InvestSMART

Rhythm Biosciences Limited (ASX:RHY)

ALERT: Price-sensitive ASX Announcement for RHY
Current share price for RHY : $0.089 -0.051 (-36.43%)+
Announcement
Release
30 Apr 2026 9:31AM
Price at Release
$0.140
Full Release
download
Summary
Rhythm Biosciences Limited has made significant strides in transitioning from a development-stage company to a commercial diagnostics business during Q3 FY26. The company achieved its first ColoSTAT® clinical revenue and expanded its partnerships internationally, notably securing distribution agreements for its geneType™ product in Southeast Asia and Australia. It also activated key infrastructures such as the 4Cyte collection network and the ColoSTAT® Access Program in Australia. The NHS England commenced an evaluation of ColoSTAT®, opening potential pathways to UK markets. Financially, the quarter was bolstered by the underwriting of RHYO options and maintaining solid cash reserves.
Key Points
  • Rhythm Biosciences transitioned to a commercial diagnostics company in Q3 FY26 with the first ColoSTAT® clinical revenue.
  • The company secured new commercial partnerships in Southeast Asia and Australia for geneType™ distribution.
  • A significant partnership with the Australian Genome Research Facility was established, enhancing domestic distribution of geneType™.
  • Rhythm Biosciences executed a supply agreement with Quansys Biosciences to support ColoSTAT® production at scale.
  • The ColoSTAT® Access Program and 4Cyte collection network have been activated to facilitate patient sample collection across Australia.
  • The NHS England has begun its evaluation of ColoSTAT®, potentially opening pathways to UK and European markets.
  • Q3 FY26 saw the commercial launch of an enhanced colorectal cancer risk assessment test.
  • The company completed the underwriting of RHYO options, strengthening its financial position.
  • Cash and cash equivalents at quarter end were reported along with related payments to directors for fees and salaries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.